Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.2471
-0.0035 (-1.40%)
At close: Oct 7, 2026, 4:00 PM EDT
0.2499
+0.0028 (1.13%)
After-hours: Oct 7, 2026, 7:43 PM EDT
Vistagen Therapeutics Employees
Vistagen Therapeutics had 41 employees as of June 30, 2026. The number of employees decreased by 16 or -28.07% compared to the same quarter last year. That makes Vistagen Therapeutics the world's 35,769th largest employer and 4,889th in the United States.
Employees
41
Change
-16
Growth
-28.07%
Revenue / Employee
$61,000
Profits / Employee
-$1,649,268
Market Cap
10.97M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 41 | -16 | -28.07% | 41 | 0 |
| Mar 31, 2026 | 41 | -16 | -28.07% | 41 | 0 |
| Dec 31, 2025 | 59 | 11 | 22.92% | 59 | 0 |
| Sep 30, 2025 | 59 | 14 | 31.11% | 59 | 0 |
| Jun 30, 2025 | 57 | 16 | 39.02% | 57 | 0 |
| Mar 31, 2025 | 57 | 17 | 42.50% | 56 | 1 |
| Dec 31, 2024 | 48 | 11 | 29.73% | 48 | 0 |
| Sep 30, 2024 | 45 | 12 | 36.36% | 45 | 0 |
| Jun 30, 2024 | 41 | 9 | 28.13% | 41 | 0 |
| Mar 31, 2024 | 40 | 6 | 17.65% | 39 | 1 |
| Dec 31, 2023 | 37 | 5 | 15.63% | 37 | 0 |
| Sep 30, 2023 | 33 | -1 | -2.94% | 33 | 0 |
| Jun 30, 2023 | 32 | -6 | -15.79% | 32 | 0 |
| Mar 31, 2023 | 34 | -2 | -5.56% | 33 | 1 |
| Dec 31, 2022 | 32 | 1 | 3.23% | 32 | 0 |
| Sep 30, 2022 | 34 | 8 | 30.77% | 34 | 0 |
| Jun 30, 2022 | 38 | 14 | 58.33% | 38 | 0 |
| Mar 31, 2022 | 36 | 15 | 71.43% | 36 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 113 |
| Cerenome | 28 |
| BioLineRx | 24 |
| Daré Bioscience | 24 |
| Passage Bio | 24 |
| Lisata Therapeutics | 21 |
| IN8bio | 18 |
| Phio Pharmaceuticals | 6 |
VTGN News
- 13 days ago - SRX Global says adds investment in Onconetix - TheFly
- 13 days ago - Vistagen presents data on fasedienol nasal spray at Psych Congress 2026 - TheFly
- 13 days ago - Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder - GlobeNewsWire
- 15 days ago - Vistagen announces preliminary data from OLE of Palisade-4 Phase 3 study - TheFly
- 15 days ago - Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire
- 27 days ago - Vistagen Therapeutics Transcript: AGM 2026 - Transcripts
- 27 days ago - Vistagen to Present at Psych Congress 2026 - GlobeNewsWire
- 7 weeks ago - Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - GlobeNewsWire